IBI-354

N/A

Report date: 2026/03/10 20:00:16

Base Information

Drug NameIBI-354
Drug Alias NameIBI-354
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload
Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursOvarian Diseases +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXinda Biomedical Technology (Hangzhou) Co LtdInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursOvarian Diseases +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A